

An MSⁿ platform for detailed characterisation of both the peptide and the glycan moieties and the peptide/glycan linkage in glycoproteins.

IMSC 2012 PTu-006

Helen V. Montgomery¹, Matthew E. Openshaw²,
Omar Belgacem², Masaki Murase³, Koichi Tanaka³.

¹Shimadzu, Mass Spec. Res. Lab, Manchester, UK;

²Kratos Analytical Ltd, Manchester, UK;

³Shimadzu Corp. , Kyoto Japan

An MSⁿ platform for detailed characterisation of both the peptide and the glycan moieties and the peptide/glycan linkage in glycoproteins.

Introduction

The analysis of glycoproteins has become essential in light of the recent developments in the biosimilars /follow-on biologics market. As increasing number of pharmaceutical companies have begun research in the field of therapeutic proteins and peptides, interest has significantly increased in terms of creating and manufacturing recombinant versions of biologically active proteins using *E. coli*, yeast, human or CHO cell expression models. Therapeutic proteins are much more complex than lower molecular weight drug compounds. The different expression models are able to produce diverse modifications (e.g glycosylation) that may

differ from those naturally found in the original innovator biopharmaceutical. The current EU and FDA regulation regarding what may be classified as a biosimilar is very strict and requires extensive characterisation of the recombinant protein, in particular the glycosylation sites, the glycan structure and the protein sequence.

The technique described here, enables the accurate determination of the glycan linkage site, the sequence of the peptide it is attached to and the precise isomeric structure of the glycan moiety. This is achieved using a combination of MSⁿ analysis and novel software solutions.

Experimental

Human apo-transferrin was reduced and alkylated prior to tryptic digestion and glycopeptide enrichment. The enriched sample was analysed by MS² and MS³ using a MALDI-QIT-TOF mass spectrometer (Axima Resonance, Shimadzu, UK). These data were investigated using in-house SIMSE software (Shimadzu Corp., Japan) for glycopeptide characterisation (glycan composition, peptide sequence and identification of the peptide glycan linkage).


In parallel, the digested sample was treated with PNGase F and the resulting glycans isolated using a combination of C18 and graphite materials and labelled with amino-pyridine. These purified glycans were analysed using Accurate Glycan Analyser - AGA (Shimadzu Corp, Japan) software-directed multi-stage MALDI mass spectrometry combining upto MS⁴ spectra to unambiguously identify the specific glycan isomeric structure.

Software solutions


CID of N-linked glycopeptides exhibits a characteristic cleavage pattern (triplet of peaks) that corresponds to a single HexNAc molecule bound to the peptide (peptide +

203 Da), the peptide linked to a ring cleaved HexNAc^(0,2X) (peptide + 83Da) and the peptide with no glycan.

An MSⁿ platform for detailed characterisation of both the peptide and the glycan moieties and the peptide/glycan linkage in glycoproteins.



SIMSE




Accurate Glycan Analyser

This triplet of peaks is used by SIMSE to determine the respective molecular weights of the glycan and the peptide moieties. Furthermore software guided *De-Novo* sequencing within SIMSE provides the peptide sequence. However, SIMSE can only provide the general composition of the glycan – mass, number of Hexose, HexNAc, etc and linkage – but not the precise isomeric structure.





For structural isomer characterisation of the glycan moiety, AGA software uses MS to MS⁴ analyses and a populated database of real MS and MSⁿ glycan spectra. Determination of the correct glycan structure is achieved using a combination of the MS and MSⁿ data, relative intensities of the fragment ions and a probabilistic scoring scheme to differentiate isomeric glycan structures.

Workflow



An MSⁿ platform for detailed characterisation of both the peptide and the glycan moieties and the peptide/glycan linkage in glycoproteins.

AGA results for human transferrin



MS, MS² and MS³ of the PA-labelled PNGaseF cleaved glycan (*m/z* 1741.66, (M+Na)⁺) using Accurate Glycan Analyser software provided the precise bi-antennary glycan structure for transferrin GP1 and GP2. Furthermore the

comparison of the MS profile for native and desialylated PA-Labelled GP1/GP2 glycans, indicates that this glycan also appears with one (*m/z* 2054.92, (M+Sia-H+2Na)⁺) and two sialic acids (*m/z* 2368.07, (M+2Sia-H+2Na)⁺) attached.

Summary of SIMSE and AGA results

Glycopeptide	Sequence /linkage	Peptide mass (M+H) ⁺	Triplet peaks	Inferred glycan mass	Glycan Structure	Glycopeptide mass (M+H) ⁺	No. of sialic acids
GP I	CGLVPLVAEN ^Y NK	1476.77	1476.77 1559.76 1679.85	1622.53		3099.34	0
						3390.44	1
						3681.55	2
GP II	QQQH ^L FGS ^N VTD ^S CGNF ^L CF ^R	2515.18	2498.18* 2581.22* 2701.29*	1622.62		4137.93	0
						4428.76	1
					Not observed	-	-

* (loss water)

An MSⁿ platform for detailed characterisation of both the peptide and the glycan moieties and the peptide/glycan linkage in glycoproteins.

Conclusion

The combination of the *Axima Resonance / Accurate* Glycan Analyser platform and SIMSE software package provides a powerful tool for complete glycoprotein characterisation. In addition to the glycopeptide sequence, this platform delivers the glycan linkage site, the glycan composition and most importantly the glycan isomeric structure.

First Edition: September, 2012